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Abstract
Background: Although 2-20% of breast cancer patients develop a contralateral breast cancer (CBC), prognosis after
CBC is still debated. Using a unique patient cohort, we have investigated whether time interval to second breast
cancer (BC2) and mode of detection are associated to prognosis.
Methods: Information on patient-, tumour-, treatment-characteristics, and outcome was abstracted from patients’
individual charts for all patients diagnosed with metachronous CBC in the Southern Healthcare Region of Sweden
from 1977-2007. Distant disease-free survival (DDFS) and risk of distant metastases were primary endpoints.
Results: The cohort included 723 patients with metachronous contralateral breast cancer as primary breast cancer
event. Patients with less than three years to BC2 had a significantly impaired DDFS (p = 0.01), and in sub-group
analysis, this effect was seen primarily in patients aged <50. By logistic regression analysis, patients diagnosed with
BC2 within routine follow-up examinations had a significantly lower risk of developing metastases compared to
those who were symptomatic at diagnosis (p < 0.0001). Chemotherapy given after breast BC1 was a negative
prognostic factor for DDFS, whereas endocrine treatment and radiotherapy given after BC2 improved DDFS.
Conclusions: In a large cohort of patients with CBC, we found the time interval to BC2 to be a strong prognostic
factor for DDFS in young women and mode of detection to be related to risk of distant metastases. Future studies
of tumour biology of BC2 in relation to prognostic factors found in the present study can hopefully provide
biological explanations to these findings.
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Background
Within their lifetime, 2-20% of breast cancer patients
develop a new tumour in their contralateral breast [1-3].
These contralateral breast cancers (CBC) are called syn-
chronous if the second tumour (BC2) develops within a
short time interval from the first tumour (BC1), and
metachronous if the time interval between tumours is
longer. In line with several previous studies, we define
metachronous tumours as CBC diagnosed at least three
months after BC1 [3-5]. However, a clear cut-off time is
not defined in the literature. CBC is today treated as a
new primary tumour (two individual tumours), but the
biological relationship between BC1 and BC2, and the
impact of a second primary tumour on prognosis is
debated [4,6-18]. Previous studies indicate that
prognosis after CBC could be associated with age, time
interval between BC1 and BC2, mode of detection of
BC2, and adjuvant treatment for BC1 [4,15-17,19]. How-
ever, despite women with a history of breast cancer have
a high lifetime risk of developing CBC, the annual risk
remains at a relative low level of 0.5-1%. A long follow-
up time is hence needed in order to obtain a large
cohort of patients with CBC.
For this study data was abstracted from individual
charts for all patients diagnosed with metachronous
CBC in the Southern Healthcare Region of Sweden (a
region with 1.7 million inhabitants) from 1977 to 2007.
This gave us a unique cohort, including more than 700
patients from multiple medical centres, providing infor-
mation on patient and tumour characteristics, treatment,
and outcome. The aims of this study were to examine
prognosis after CBC in relation to time interval between
* Correspondence: lisa.ryden@med.lu.se
3Department of Surgery, Clinical Sciences, Lund, Lund University, Sweden
Full list of author information is available at the end of the article
Alkner et al. BMC Cancer 2011, 11:114
http://www.biomedcentral.com/1471-2407/11/114
© 2011 Alkner et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.




Inclusion criteria were patients within the Southern
Swedish Healthcare Region with two breast cancers
reported in the Swedish Cancer Register, with the sec-
ond tumour diagnosed between 1977 and 2007. The
Swedish Cancer Register is a nationwide database
including the International Classification of Diseases
code and date of diagnosis. The study cohort includes
patients from 14 hospitals (Lund, Malmö, Helsingborg,
Ängelholm, Landskrona, Ystad, Trelleborg, Hässleholm,
Kristianstad, Växjö, Ljungby, Halmstad, Karlshamn, and
Karlskrona) within the Southern Healthcare Region of
Sweden. All hospitals were active members of the South
Sweden Breast Cancer Group, established in 1977, and
used the common guidelines for diagnosis, treatment,
and follow-up. The follow-up program included annual
physical examination and mammogram. From 1977 to
1995 the recommended follow-up period was ten years,
which was down-scaled to five years from 1995 to 2002,
and three years from 2002 onwards. The regular surveil-
lance program was additionally followed by admittance
to the screening program for mammographic examina-
tions every 24 months.
The cohort retrieved from the register initially
included 1970 patients. The flow-chart of the study is
given in Figure 1. After exclusion according to prede-
fined exclusion criteria, our cohort included 723
patients with metachronous contralateral breast cancer
as primary event. For patients with multiple exclusion
criteria, the first criterion mentioned in the chart is
listed in Figure 1.
Data abstraction of clinical information
From September 2007 to November 2009, data was
abstracted from individual charts (clinical notes, pathol-
ogy-, and X-ray-records) in a systematised manner,
using a predefined protocol. The protocol was designed
at the Department of Medical Epidemiology and Biosta-
tistics, KI Stockholm, for collecting data from patients
with CBC. Individual charts at the Departments of sur-
gery as well as the Departments of oncology (Lund and
Malmö) were retrieved, in order to optimise data
abstraction and minimise patients lost to follow-up. The
protocol used included data on mode of detection as
well as surgical and oncological treatment for BC1 and
BC2. Patients diagnosed within a follow-up programme
were considered asymptomatic at time of diagnosis,
whereas patients who first noted symptoms themselves
and thereafter contacted their physicians were consid-
ered symptomatic. Patients were considered to have
received endocrine treatment only if they had continued
treatment for at least three months. Due to the long fol-
low-up period of the study cohort, oestrogen receptor
status for both tumours were available for less than half
of the patients, and histological grade for less than one
third. Additionally, scoring methods to determine histo-
logical grade differed during the study follow-up period
and between various pathology departments. Neither
oestrogen receptor status, nor histological grade, was
hence used for further statistical analysis in the present
study.
Previous studies use different time intervals to BC2 to
separate early from late metachronous CBC. A time
interval of three years has been used for a multitude of
previous studies [13,15,16], and this interval was hence
selected for all analysis presented in this report. Unless
otherwise stated, age refers to the age at diagnosis of
BC1, in line with earlier studies [4,14,16,20]. To examine
the effect of calendar period at diagnosis of CBC on
prognosis, we divided the material into three calendar
periods, 1977 to 1986, 1987 to 1996, and 1997 to 2007.
Ethical Considerations
This project has been approved by the ethical commit-
tee of Lund University (LU 240-01). All information and
data was handled confidentially, and evaluation of infor-
mation linked to patients was carried out in accordance
with the Swedish Personal Data Act (Personuppgiftslagen
in Swedish).
End-points and follow-up
Distant disease-free survival (DDFS) was chosen as pri-
mary end-point of the study. DDFS includes develop-
ment of distant metastases (visceral, skeletal, brain, or
cutaneous metastases) as a primary event. Loco-regional
recurrences were not regarded as events in analysis of
DDFS, and event-free survival was measured from diag-
nosis of CBC. Survival from BC1 was not considered
since that would automatically prolong the follow-up
until event for patients with a longer time interval
between tumours, and hence bias the results. If no prior
event was recorded, DDFS was calculated to the last fol-
low-up date in the patient’s individual chart. For
patients who developed a malignancy other than breast
cancer after diagnosis of CBC, the diagnosis date of this
malignancy was considered to be the last follow-up date.
Statistical Analysis
For statistical calculations, the software package Stata 10.1
(StataCorp. 2008. College Station, TX, USA) was used.
Kaplan-Meier plots were used to describe DDFS and the
log-rank test was used to evaluate hypotheses of equal sur-
vival. Kaplan-Meier curves were curtailed when less than
five individuals remained at risk. Cox regression was used
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to estimate hazard ratios (HR), and assumptions of pro-
portional hazards were checked graphically. Retrospective
studies of prognosis in relation to mode of detection could
be affected by lead-time bias (earlier detection leads to a
longer follow-up until event, even if disease progression is
the same). To avoid this we looked at the risk of distant
metastasis as a primary event instead of DDFS in relation
to mode of detection. Logistic regression was therefore
used to compare risk of metastasis in different sub-groups.
Multivariate analyses presented do not include patients
Figure 1 Flow-chart of inclusion vs. exclusion in the study cohort.
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with missing values for any of the variables included.
However, the analyses were repeated for all patients by
treating the missing category for discrete variables as a
separate category and by imputing the sample mean over
all patients for continuous variables. To assess whether the
effect of time interval to BC2 or mode of detection differed
with age, a Cox model was used with a term for interac-
tion between each of these factors and age. Age was cate-
gorised as over or equal to vs. under age 50 at diagnosis of
BC1. All p-values correspond to two-sided tests and values
less than 0.05 were considered significant.
Results
Clinical information
Patient, tumour and treatment characteristics are
described in Table 1. The median duration of follow-up
after BC2 was 5.6 years (IQR 2.0-9.1) for all patients
without an event. Median duration of follow-up for
patients with a time interval to BC2 less than three
years was 7.0 years, and for those with a time interval to
BC2 of three years or more, 5.4 years. The median time
to development of metastasis after BC2 was 2.2 years.
For patients operated for BC1, 524 patients (73%)
received surgery with a modified radical mastectomy
and 193 (27%) breast conserving surgery. The corre-
sponding numbers for BC2 were 498 (71%) with modi-
fied radical mastectomy and 206 (29%) breast
conserving surgery. Endocrine treatment included
tamoxifen, aromatase inhibitors, and/or ooforectomy.
For over 80% of patients the endocrine treatment given
was tamoxifen.
Mode of detection of BC2 was known for 692 patients.
Of these, 250 patients first noted the symptoms them-
selves, 97 patients were diagnosed by clinical examina-
tion, 257 patients by clinical mammography during
follow-up, and 70 patients by screening mammography
after re-admittance to the screening programme. Eigh-
teen patients were diagnosed by other means (such as
prophylactic mastectomy, or examination for other
symptoms). These patients, along with 31 patients with
missing data, were excluded from further analysis in
regard to mode of detection. Patients who first noted
symptoms themselves were considered symptomatic,
while those diagnosed with clinical examination or
mammography were considered asymptomatic at
diagnosis.
Time interval between first and second breast cancer in
relation to prognosis
The time interval between BC1 and BC2 was 0.30-36
years, with a median of 6.7 years. A time interval of less
than five years was most common (42%) between diag-
nosis of BC1 and BC2, with a decline in the percentage
of patients diagnosed with BC2 the longer the time
interval to BC2 (5-9 years 24%, 10-14 years 16%, 15-19
years 9%, 20-24 years 5%, 25-29 years 2%, 30-34 years
1%, and ≥35 years 0%). Patient and tumour characteris-
tics in relation to time interval to BC2 are described in
Table 2.
When exploring the time interval to BC2 as a continu-
ous variable, we found a significantly improved DDFS
per year the longer the time interval to BC2 (HR = 0.97,
p = 0.002, 95% CI 0.94-0.99). This result remained sta-
tistically significant in multivariate analysis adjusted for
age, calendar period, mode of detection of BC2, tumour
size, lymph node status, and treatment for BC1 and BC2
(HR = 0.94, p < 0.001, 95% CI 0.91-0.97). When dividing
the time interval ≥3 years to BC2 into two separate cate-
gories, 3-9 years and ≥10 years, we found that DDFS
seems to improve continuously with increasing time
interval to BC2. Compared to patients with a time inter-
val to BC2 of ≥10 years (the selected reference group),
patients with a time interval of 3-10 years had a HR of
1.3 (p = 0.1, 95% CI 0.95-1.9), whereas patients with a
time interval of less than three years had a HR of 1.7 (p
= 0.003, 95% CI 1.2-2.4).
Patients with a time interval to BC2 of less than three
years had a significantly impaired DDFS compared to
patients with a time interval of more than three years
(Figure 2, Table 3). Statistical significance remained in
multivariate analysis adjusted for age, calendar period,
mode of detection of BC2, tumour size, lymph node sta-
tus, and treatment for BC1 and BC2 (Table 3).
Subgroup analysis showed that women younger than
50 years when diagnosed with BC1 had a significantly
worse DDFS if the time interval to BC2 was less than
three years (Figure 3, Table 3). This result remained sta-
tistically significant in multivariate analysis (Table 3).
However, for women of 50 years or older, no significant
difference was seen in regard to time interval to BC2 -
neither in univariate- nor multivariate analysis (Figure 3,
Table 3). When using a Cox model with main effects
for age and time interval to BC2, and a term for the
interaction between these variables, the interaction was
statistically significant (HR = 0.53, p = 0.03, 95% CI
0.30-0.94). However, when the data was adjusted for
calendar period, mode of detection of BC2, tumour size,
lymph node status, and treatment for BC1 and BC2, no
statistical significance remained. Multivariate analyses
were repeated to include patients with missing values,
indicating similar results as above.
Menopausal status at diagnosis of both BC1 and BC2
was known for 611 patients (85%). Repeating analyses
according to menopausal status, results for premenopau-
sal patients and patients who switched menopausal sta-
tus between tumours were similar to those observed for
patients <50 years at BC1, while results for postmeno-
pausal patients were similar to those observed for
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patients ≥50 years (data not shown). Out of the 198
patients who were <50 years old at BC1, only 9 (5%)
were postmenopausal, whereas for the 466 patients ≥50
years of age at BC1, only 43 (9%) were premenopausal.
An age-limit of 50 years hence seems to effectively sepa-
rate pre- and postmenopausal women.
Mode of detection in relation to prognosis
For 424 (63%) of the patients, CBC was diagnosed
within a follow-up programme, whereas 250 patients
(37%) first noted symptoms themselves and thereafter
contacted their physician. The median duration of fol-
low-up after BC2 for patients without an event was 5.4
years for symptomatic patients, and 5.7 years for asymp-
tomatic patients. Patient and tumour characteristics are
described in Table 2.
Patients with symptoms at diagnosis were younger and
had a longer time interval between tumours. Additionally
their contralateral tumours were larger, and more often
combined with the occurrence of lymph node metastases
Table 1 Patient, tumour, and treatment characteristics in relation to development of metastasis after BC2
First breast cancer, No (%) Second breast cancer, No (%)
Metastasis No metastasis Metastasis No metastasis
No = 723 No = 210 No = 513 No = 210 No = 513
Diagnosis
<1977 37 (18) 97 (19) 0 0
1977-1986 66 (31) 161 (31) 53 (25) 95 (19)
1987-1996 79 (38) 191 (37) 78 (37) 179 (35)
1997-2007 28 (13) 64 (12) 79 (38) 239 (47)
Age (years)
Median (range) 52 (27-85) 60 (30-90) 60 (32-92) 70 (32-98)
<50 94 (45) 123 (24) 50 (24) 34 (7)
≥50 116 (55) 390 (76) 160 (76) 479 (93)
Menopausal status
Premenopausal 100 (51) 132 (28) 29 (16) 32 (7)
Postmenopausal 96 (49) 336 (72) 148 (84) 440 (93)
Missing 14 45 33 41
Node status
N0 105 (53) 330 (72) 97 (50) 292 (73)
N+ 92 (47) 130 (28) 96 (50) 106 (27)
Missing 13 53 17 115
Size (mm)
Median (range) 20 (1-90) 15 (1-100) 18 (1-110) 14 (1-90)
Missing 28 50 17 20
Surgery
Modified radical mastectomy 162 (78) 362 (71) 158 (75) 340 (66)
Partial mastectomy 44 (21) 149 (29) 45 (21) 161 (31)
No Surgery 1 (0.5) 0 6 (3) 12 (2)
Missing 3 2 1 0
Radiotherapy
No 56 (27) 213 (42) 122 (58) 360 (70)
Yes 153 (73) 293 (58) 87 (42) 152 (30)
Missing 1 7 1 1
Chemotherapy
No 172 (82) 473 (94) 178 (85) 491 (96)
Yes 37 (18) 32 (6) 31 (15) 21 (4)
Missing 1 8 1 1
Endocrine treatment No 158 (76) 391 (77) 132 (64) 296 (58)
Yes 51 (24) 114 (23) 74 (36) 215 (42)
Missing 1 8 4 2
Abbreviations: No number, N+ lymph node metastases, N0 no lymph node metastases, node status lymph node status.
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(Table 2). Using logistic regression, a significantly higher
risk of developing metastases was seen in patients who
were symptomatic at diagnosis (Table 4). The statistical
significance remained when adjusting for age, calendar
period, tumour size, node status, and treatment for both
tumours. This suggests that finding BC2 at an earlier
stage is not the only factor improving prognosis in
patients asymptomatic at diagnosis. Multivariate analyses
were repeated to include patients with missing values. All
analyses yielded similar results as described above.
Mode of detection remained a significant risk factor
for development of distant metastases when the time
Table 2 Patient, tumour, and treatment characteristics in relation to time interval to and mode of detection of the
second breast cancer
Time interval to second breast cancer Mode of detection of second breast cancer a




First breast cancer, No (%) Second breast cancer, No
(%)
<3 years ≥3 years <3 years ≥3 years Symptomatic Asymptomatic Symptomatic Asymptomatic
No = 200 No = 523 No = 200 No = 523 No = 250 No = 424 No = 250 No = 424
Diagnosis of BC2
<1977 1 (1) 133 (25) 0 0 70 (28) 55 (13) 0 0
1977-1986 59 (30) 168 (32) 48 (24) 100 (19) 77 (31) 132 (31) 57 (23) 79 (19)
1987-1996 84 (42) 186 (36) 80(40) 177 (34) 84 (34) 174 (41) 89 (36) 150 (35)
1997-2007 56 (28) 36 (7) 72 (36) 246 (47) 19 (8) 63 (15) 104 (42) 195 (46)
Age
Median (range) 59 (39-89) 57 (27-90) 60 (32-91) 69 (36-98) 54 (27-89) 59 (30-87) 66 (35-97) 68 (32-93)
<50 years 55 (28) 162 (31) 48 (24) 36 (7) 96 (38) 110 (26) 45 (18) 34 (8)
≥50 years 145 (73) 361 (69) 152 (76) 487 (93) 154 (62) 314 (74) 205 (82) 390 (92)
Node status
N0 111 (60) 324 (69) 108 (65) 281 (66) 161 (72) 253 (65) 117 (56) 251 (71)
N+ 75 (40) 147 (31) 59 (35) 143 (34) 62 (28) 138 (35) 91 (44) 104 (29)
Missing 14 52 33 99 27 33 42 69
Size (mm)
Median (range) 17 (1-100) 17 (1-70) 14 (1-110) 15 (1-85) 18 (1-90) 17 (1-100) 19 (1-110) 13 (1-90)
Missing 6 72 10 27 38 32 12 19
Radiotherapy
No 89 (45) 180 (35) 121 (61) 361 (69) 96 (39) 153 (36) 158 (63) 283 (67)
Yes 111 (56) 335 (65) 79 (40) 160 (31) 152 (61) 268 (64) 91 (37) 141 (33)
Missing 0 8 0 2 2 3 1 0
Chemotherapy
No 167 (84) 478 (93) 177 (89) 492 (94) 227 (92) 376 (89) 220 (88) 402 (95)
Yes 33 (17) 36 (7) 23 (12) 29 (6) 20 (8) 45 (11) 29 (12) 22 (5)
Missing 0 9 0 2 3 3 1 0
Endocrine treatment
No 148 (74) 401 (78) 124 (63) 304 (59) 202 (82) 313 (74) 146 (59) 249 (59)
Yes 52 (26) 113 (22) 74 (37) 215 (41) 45 (18) 108 (26) 102 (41) 172 (41)
Missing 0 9 2 4 3 3 2 3
Mode of detection of BC2
Symptomatic 57 (31) 193 (40)
Asymptomatic 129 (69) 295 (60)
Missing 14 35
Time interval to BC2
Median (range) 9.1 (0.37-36) 5.8 (0.30-34)
<3 years 57 (23) 129 (30)
≥3 years 193 (77) 295 (70)
a 49 patients were excluded from analyses regarding mode of detection due to missing data or diagnosis by other means than mammography, clinical
examination or symptoms noted by the patient.
Abbreviations: N+ lymph node metastases, N0 no lymph node metastases, No number, node status lymph node status.
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Figure 2 Distant disease-free survival in relation to time interval to BC2. Abbreviations: BC2 the second breast cancer, DDFS distant
disease-free survival, Interval time interval to BC2.
Table 3 Cox-regression analysis for distant metastasis in relation to time interval to the second breast cancer
Age at BC1 Time interval to Cases Metastasis Metastasis/100.000 HR HR* HR**
BC2 No No (%) person-years (95% CI) (95% CI) (95% CI)
All <3 years 200 74 (37) 5800 1.4 (1.1-1.9) 1.6 (1.1-2.2) 1.6 (1.1-2.3)
No = 723 ≥3 years 523 136 (26) 4100 1.0 1.0 1.0
p = 0.01 p = 0.009 p = 0.01
< 50 years <3 years 55 34 (62) 11000 2.2 (1.4-3.4) 2.0 (1.2-3.4) 2.2 (1.2-3.8)
No = 217 ≥3 years 162 60 (37) 4900 1.0 1.0 1.0
p < 0.0001 p = 0.01 p = 0.006
≥ 50 years <3 years 145 40 (28) 4100 1.2 (0.78-1.7) 1.5 (0.92-2.3) 1.3 (0.77-2.2)
No = 506 ≥3 years 361 76 (21) 3700 1.0 1.0 1.0
p = 0.5 p = 0.1 p = 0.3
* Adjusted for calendar period (1977-1986, 1987-1996, 1997-2007), age (under vs. over 50 years at diagnosis of BC1), mode of detection of BC2 (symptomatic vs.
asymptomatic), size (mm) of BC1 and BC2, and node status (N0 vs. N+) for BC1 and BC2. Multivariate analyses in subgroups divided by age are not adjusted for
age again. No = 471, 158 patients <50 years and 313 ≥50 years.
** Adjusted for factors listed under * and in addition: treatment for BC1 and BC2 (radiotherapy, chemotherapy, endocrine treatment, yes vs. no for each of the
variables). Multivariate analyses in subgroups divided by age are not adjusted for age again. No = 468, 157 patients <50 years and 311 ≥50 years.
Abbreviations: BC1 first breast cancer, BC2 second breast cancer, CI confidence interval, HR hazard ratio, N+ lymph node metastases, N0 no lymph node metastases,
No number, node status lymph node status.
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interval ≥3 years to BC2 was divided into 2 separate
categories; 3-9 years and ≥10 years, with a time interval
of less than three years selected as reference group (3-9
years; HR = 2.2, p = 0.005 95% CI 1.3-4.0. ≥10 years;
HR = 3.0, p = 0.001, 95% CI 1.5-5.8).
When comparing mode of detection for patients diag-
nosed by clinical examination with those diagnosed by
mammography, patients diagnosed by mammography
were younger, had smaller tumours, and more seldom
lymph node metastases of BC2 (data not shown).
Additionally the risk of later metastasis was slightly,
though not significantly, higher for patients diagnosed
by clinical examination
Association between adjuvant treatment and prognosis
A multivariate Cox-regression analysis adjusted for time
interval between tumours, calendar period of diagnosis,
mode of detection of BC2, age at BC1, lymph node status,
tumour size, and treatment for BC1 and BC2, showed che-
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Figure 3 Distant disease-free survival in relation to age and time interval to BC2. Age refers to age at diagnosis of BC1. Abbreviations:
BC2 the second breast cancer, DDFS distant disease-free survival, Interval time interval to BC2.
Table 4 Logistic regression analysis for risk of metastasis in relation to mode of detection and time interval to the
second breast cancer
Patients groups Mode of detection Cases Metastasis OR OR* OR**
No No (%) (95% CI) (95% CI) (95% CI)
All Symptomatic 250 98 (39) 2.1 (1.5-3.0) 2.0 (1.3-3.1) 2.1 (1.3-3.3)
No = 674 Asymptomatic 424 99 (23) 1.0 1.0 1.0
p < 0.0001 p = 0.002 p = 0.002
< 3 years to BC2 Symptomatic 57 30 (53) 2.4 (1.3-4.5) 1.7 (0.71-4.1) 1.7 (0.67-4.2)
No = 186 Asymptomatic 129 41 (32) 1.0 1.0 1.0
p = 0.008 p = 0.2 p = 0.3
≥ 3 years to BC2 Symptomatic 193 68 (35) 2.2 (1.5-3.4) 2.2 (1.3-3.8) 2.3 (1.3-4.0)
No = 488 Asymptomatic 295 58 (20) 1.0 1.0 1.0
p < 0.0001 p = 0.003 p = 0.003
< 50 years at BC1 Symptomatic 96 53 (55) 2.2 (1.3-3.9) 1.5 (0.68-3.3) 1.4 (0.62-3.4)
No = 206 Asymptomatic 110 39 (35) 1.0 1.0 1.0
p = 0.005 p = 0.3 p = 0.4
≥50 years at BC1 Symptomatic 154 45 (29) 1.7 (1.1-2.7) 2.2 (1.2-3.9) 2.3 (1.3-4.1)
No = 468 Asymptomatic 314 60 (19) 1.0 1.0 1.0
p = 0.01 p = 0.006 p = 0.006
* Adjusted for calendar period (1977-1986, 1987-1996, 1997-2007), age (under vs. over 50 years at diagnosis of BC1), size (mm) of BC1 and BC2, and node status
(N0 vs. N+) for BC1 and BC2. No = 471, 138 patients with <3 years to BC2, and 333 patients with ≥3 years to BC2, 158 patients <50 years and 313 ≥50 years.
** Adjusted for HR* and in addition: treatment for BC1 and BC2 (radiotherapy, chemotherapy, endocrine treatment, yes vs. no for each of the variables.). No =
468, 137 patients with <3 years and 331 patients with ≥3 years to BC2, 157 patients <50 years and 311 ≥50 years.
Abbreviations: BC1 first breast cancer, BC2 second breast cancer, CI confidence interval, DDFS distant disease-free survival, N+ lymph node metastases, N0 no lymph
node metastases, No number, node status lymph node status, OR odds ratio
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prognostic factor for DDFS (HR = 2.1, p = 0.008, 95% CI
1.2-3.6). Radiotherapy delivered after BC1 did not reach
statistical significance as a prognostic factor for DDFS (HR
= 1.5, p = 0.07, 95% CI 0.98-2.3), and endocrine adjuvant
treatment given after BC1 was not linked to DDFS (HR =
1.2, p = 0.5, 95% CI 0.74-1.9). However, adjuvant radio-
therapy (HR = 0.6, p = 0.007, 95% CI 0.41-0.87) and endo-
crine treatment (HR = 0.5, p = 0.001, 95% CI 0.33-0.74)
after BC2 were positive prognostic factors, whereas che-
motherapy given after BC2 had no effect on DDFS (HR =
0.88, p = 0.6, 95% CI 0.50-1.5). Multivariate analyses were
repeated to include patients with missing values with simi-
lar results as described above.
Discussion
Using a large population-based cohort, including patient,
tumour, and treatment information, we have studied
prognosis after CBC in relation to time interval to, and
mode of detection of BC2. A short time interval to BC2
was proven to be a significant negative prognostic fac-
tor, supporting earlier studies [4,15-17]. However sub-
group analysis indicates that this effect is seen only for
younger women. Data additionally indicate that women
diagnosed by routine follow-up examination, have a sig-
nificantly lower risk of developing metastases at a later
stage.
In line with our data, previous studies have found a
short time interval to BC2 to be associated with an
impaired prognosis [4,15-17]. This study includes
extended individual data from a large population-based
cohort and strongly validate that a short time interval to
BC2 is a negative prognostic factor. Time interval to
BC2 was analysed both as a continuous and as a dichot-
omised variable with a cut-point of three years, and
yielded independent prognostic information by both
methods. Furthermore, previous results have differed
when comparing prognosis after synchronous, meta-
chronous, and unilateral breast cancer [10]. However,
there have been indications that synchronous breast
cancer (defined as CBC diagnosed within 3-12 months
after BC1) might result in a worsened prognosis com-
pared to metachronous breast cancer [10,11,18].
The underlying cause for the impaired prognosis
observed for CBC diagnosed within a short time interval
from BC1 is unclear. One potential explanation could be
that these tumours more often represent a metastatic
spread of BC1. Comparisons of genetic alternations in
bilateral breast cancer have shown that although most
CBCs represent a new primary tumour, contralateral
spreading from BC1 does occur [6-9]. A short time
interval to BC2 has also been found to correlate with
increased genetic and morphological similarities between
bilateral tumours [21,22]. This could suggest a higher
prevalence of metastatic spread, but could also be a
result of these tumours having developed in a similar
biological environment. Imyanitov et al. found the high-
est correlation between tumours in women who devel-
oped both tumours while premenopausal [21]. If this
correlation results from a higher percentage of contral-
ateral metastatic spread in these patients, it could par-
tially explain the different effects of time interval to BC2
observed for the different age categories in our study,
where most patients (95%) diagnosed when under 50
years of age were premenopausal. However, Imyanitov
et al. observed the lowest correlation between bilateral
tumours separated by menopause, making hormonal
environment at the time of development another likely
cause to similarities vs. differences observed [21].
Another potential explanation could be that CBC
diagnosed during, or soon after, adjuvant treatment has
developed resistance to treatment and a more aggressive
phenotype. The incidence of CBC in Sweden has
decreased since the early 1980s [4]. This observation is
potentially resulting from an increased use of adjuvant
treatment, reducing the risk of CBC [2,3,23-25]. How-
ever, during the same time period mortality increased
for those women who did develop CBC [4], which could
reflect a treatment-escape phenomenon once therapy
has failed to prevent a second tumour. CBC developed
after tamoxifen treatment is also ER-negative to a larger
extent [2,26-28], indicating that treatment given for BC1
affect the biology of BC2. If younger patients have
received more adjuvant treatment, this might hence be
one explanation to why the time interval between
tumours is of greater importance in younger patients. In
the present cohort we found support for this theory in
that BC1 in younger patients was more often treated
with radiotherapy and chemotherapy, while older
women received more endocrine therapy (data not
shown).
In this study chemotherapy given for BC1 was an
independent negative prognostic factor, though this was
not seen if chemotherapy had been given for BC2. Adju-
vant endocrine treatment after BC1, however, had no
effect on prognosis after BC2. Radiotherapy and endo-
crine treatment were positive prognostic factors if given
after BC2, but not if given after BC1. Similar results
have been seen in a study by Hartman et al and this
could be interpreted as an indication that a CBC diag-
nosed after prior chemotherapy is more aggressive [4].
However, choice of adjuvant therapy is strongly depen-
dent on tumour stage and biology, and patients selected
to receive chemotherapy are those with the worst pre-
dicted prognosis. The survival analysis is adjusted for
several prognostic factors including tumour stage and all
treatment given. There are however still other factors,
affecting prognosis and choice of therapy (hormone
receptor status, histological grade, etc.) which are not
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provided for all patients in the present study, including
patients for several decades. Hence, although these
results are interesting and in line with those found by
Hartman et al [4], they need to be interpreted with cau-
tion and further studies are required. The effect on
prognosis by adjuvant endocrine treatment for BC1 is
not fully elucidated since the cohort was not stratified
according to hormone receptor status. Future studies
including biomarker analysis of BC1 and BC2 can hope-
fully shed some light on this issue and, more impor-
tantly, on the effect of adjuvant treatment after BC1 on
tumour biology of BC2.
Although early detection of distant metastases does
not affect survival or quality of life [29,30], recent stu-
dies suggest that early detection of local recurrences or
CBC does improve prognosis [19,31,32]. However,
results are not unanimous [33-35]. Previous studies are
retrospective, leading to problems with lead-time (earlier
detection results in a longer follow-up until event, even
if the disease progression is the same) and length-time
bias (slower growing tumours will be more easily
detected, since they are detectable over a longer time
period). To avoid lead-time bias we have looked at the
risk of metastasis, using logistic regression, instead of
DDFS with regard to mode of detection. Length-time
bias may still be a problem in our study, although pre-
vious studies have not shown this to be a major source
of concern [32,36-38]. We found that significantly fewer
patients diagnosed with CBC within follow-up examina-
tions subsequently developed metastases, which is prob-
ably to a large extent due to the fact that the tumours
were discovered at an earlier stage. However, mode of
detection remained a significant prognostic factor even
after adjusting for tumour size, node status, and treat-
ment for both tumours. This finding is in line with data
from unilateral breast cancer, where diagnosis by
screening mammography has been shown to be an inde-
pendent prognostic factor even after adjustment for dis-
ease stage [39-42].
Presuming that surveillance after breast cancer diag-
nosis is effective, how long should it continue? In Swe-
den, a follow-up time of ten years was advocated until
the mid-1990s. Today, clinical surveillance is often
reduced to five years or less, followed by mammo-
graphic surveillance every 24 months within a screening
program. In this study we found mode of detection to
be associated with risk of metastasis even when BC2
was diagnosed more than ten years after BC1, suggesting
that a long follow-up time could be of value.
The present study was based on a unique cohort,
including over 700 patients with CBC, with information
on patient and tumour characteristics, treatment, and
outcome. Despite the large selection of patients and
information included in this study, some potential
sources of bias should be considered. For example, sub-
group analysis will include fewer events. Inclusion in the
cohort was based on data from the Swedish Cancer Reg-
ister which is nationwide. However, some cases of CBC
might still be missing or misclassified, and 150 charts
were never found. Although data from the patients’ indi-
vidual charts is probably more reliable than register
data, the quality of clinical notes and pathological
records varied over time and between physicians. Due to
the low annual incidence of contralateral breast cancer,
a long period of follow-up was needed to receive a large
cohort. Hence, standard surgical methods, routine histo-
pathological analysis and adjuvant treatment have chan-
ged during the study period. The patients were included
in the cohort based on diagnose date of the CBC.
Hence, for women initially treated before 1977, there
could be a selection of patients with a longer time inter-
val to BC2. When adjusting our analyses for diagnose
date of BC1 the multivariate analysis of time interval to
BC2 including all patients and treatment was no longer
significant. Otherwise significance in all other analysis
remained constant.
Conclusions
Patients with CBC are currently treated according to the
tumour biology of BC1 and BC2 individually, and it is
controversial whether prognosis after CBC is worse than
after unilateral breast cancer [4,10-18]. Our study was
based on clinical data from individual patients and
results indicate that the time interval to BC2, especially
for patients younger than 50 years, is a strong prognos-
tic factor. Additionally, mode of detection was proven to
be closely related to the risk of developing metastases.
By taking time interval to BC2 and mode of detection
into account when diagnosing patients with CBC, this
study seems to have identified patients with a poor
prognosis. Indeed, among patients diagnosed with symp-
tomatic CBC within three years from BC1, more than
50% later developed metastases. Further translational
studies of the tumour biology of BC2 in relation to time
interval, adjuvant treatment after BC1 and mode of
detection are needed to confirm and explain these
results.
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